Achieving pCR is a central goal of neoadjuvant therapy in early-stage human epidermal growth factor 2 (HER2)-positive breast cancer [1], as it is associated with improved long-term outcomes, including progression-free survival (PFS) and overall survival (OS), and can facilitate tumor downstaging [2,3]. The gene discussed is ERBB2; the disease is breast cancer.